Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GRSF1 Protects Against Heart Failure by Maintaining BCAA Homeostasis.

Circulation·2026
Same author

Insulin Resistance and Blood Pressure Control on Cognitive Outcomes.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Sandwich-type electrochemical biosensor for glycoproteins detection based on dual-amplification of boronic acid-gold nanoparticles and dopamine-gold nanoparticles.

Biosensors & bioelectronics·2013
Same author

Ultrastructural study on dynamics of lipid bodies and plastids during ripening of chili pepper fruits.

Micron (Oxford, England : 1993)·2013
Same author

Resveratrol protects against age-associated infertility in mice.

Human reproduction (Oxford, England)·2013
Same author

Receptor for advanced glycation end products: a new theraputic target for chronic obstructive pulmonary disease?

Archives of medical research·2013
Same journal

Correction: A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.

Journal of cardiovascular translational research·2026
Same journal

ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.

Journal of cardiovascular translational research·2026
Same journal

The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.

Journal of cardiovascular translational research·2026
Same journal

Extracellular Vesicles Link Cerebral Ischemia to Coronary Microvascular Dysfunction - Role for RGD Motif-Activated Endothelin Signaling.

Journal of cardiovascular translational research·2026
Same journal

Tracing the pathogenic PLN p.(Arg14del) variant across the globe; more than just a local curiosity.

Journal of cardiovascular translational research·2026
Same journal

Immunometabolic Remodeling in Ischemic and Non-Ischemic Heart Failure.

Journal of cardiovascular translational research·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Metabolic Heterogeneity Across Heart Failure Subtypes Defined by Integrative Multi-Omics Analysis.

Yuzhou Xue1, Lin Liu2, Ming Xu3

  • 1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China.

Journal of Cardiovascular Translational Research
|July 1, 2026
PubMed
Summary
This summary is machine-generated.

Distinct lipid metabolites increase heart failure (HF) risk, while tricarboxylic acid (TCA) cycle intermediates may protect. Metabolic signatures vary by HF cause, with OGDHL identified as a key regulator in cardiac remodeling.

Keywords:
Heart failureMendelian randomizationMetabolic heterogeneityMetabolomicsOGDHLSingle-cell RNA-seq

Related Experiment Videos

Last Updated: Jul 2, 2026

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Area of Science:

  • Cardiovascular Science
  • Metabolomics
  • Genetics

Background:

  • Heart failure (HF) is a complex syndrome with varied causes, but its specific metabolic underpinnings remain poorly understood.
  • Identifying subtype-specific metabolic differences is crucial for targeted therapeutic strategies.

Purpose of the Study:

  • To elucidate the metabolic signatures associated with different subtypes of heart failure.
  • To identify novel molecular regulators of cardiac metabolic remodeling in HF.

Main Methods:

  • Integrative multi-omics analysis combining metabolomics, genetics, and single-cell transcriptomics.
  • Mendelian randomization analysis of 1,091 circulating metabolites.
  • Analysis of subtype-specific metabolic pathways in coronary heart disease (CHD), hypertension (HTN), and overweight-related HF.

Main Results:

  • Sphingolipids were linked to increased HF risk, whereas tricarboxylic acid (TCA) cycle intermediates showed potential protective effects.
  • Distinct metabolic profiles were observed: lipid remodeling in CHD-HF, TCA metabolism in HTN-HF, and amino acid pathways in overweight-related HF.
  • Candidate regulators including UPP1, NEU3, CBS, SHMT1, PLD2, OGDHL, and SULT1A1/2 were identified; OGDHL, enriched in cardiomyocytes, was downregulated in experimental HF.

Conclusions:

  • Metabolic heterogeneity significantly contributes to distinct heart failure subtypes.
  • OGDHL emerges as a potential key regulator of cardiac metabolic remodeling in heart failure.